[Form 4] Nurix Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Nurix Therapeutics director Julia P. Gregory reported a transaction on 09/17/2025 showing acquisition of 10,750 shares of common stock. The filing indicates a director stock option with an exercise/conversion price of $1.86 was exercised (transaction code M), resulting in 10,750 shares acquired and 10,750 shares owned following the transaction. The option covers the right to buy 10,750 shares and lists an expiration date of 12/22/2029. The filing notes the option vested monthly beginning September 12, 2019 and fully vested on August 12, 2023.

Positive

• Director acquired 10,750 shares via exercise, showing insider ownership increase
• Exercise price disclosed at $1.86 and option expiration date 12/22/2029 provide clear terms
• Vesting schedule provided (monthly from 9/12/2019; fully vested 8/12/2023) clarifies origin of transaction

Negative

• None.

Insights

Securities Analyst

TL;DR: Director exercised vested options to acquire 10,750 shares at $1.86; routine insider activity.

The report documents a standard exercise of a previously granted director stock option (code M). The exercise price of $1.86 and the underlying 10,750 common shares are explicitly stated, with the option expiring 12/22/2029. This is a non-derivative acquisition resulting from exercising vested options, not a market purchase, so it reflects compensation realization rather than a new capital allocation by the director.

Corporate Governance Expert

TL;DR: Transaction is a completed vesting and exercise of a director option; governance implications are routine.

The filing clarifies vesting chronology: monthly vesting from 9/12/2019 and full vesting on 8/12/2023. That timeline explains the exercise action on 9/17/2025. As a director-level option exercise, this is a common form of equity compensation realization and does not by itself indicate change in ownership control or unusual governance events.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

GREGORY JULIA P

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1700 OWENS STREET, SUITE 205

(Street)

SAN FRANCISCO CA 94158

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/17/2025		M		10,750	A	$1.86	10,750	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$1.86	09/17/2025		M			10,750	(1)	12/22/2029	Common Stock	10,750	$0	22,583	D

Explanation of Responses:

1. The stock option vested as to 1/48 of the total shares monthly beginning September 12, 2019, and was vested in full on August 12, 2023.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Julia P. Gregory	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Julia P. Gregory report on Form 4 for NRIX?

The Form 4 reports Ms. Gregory exercised a director stock option to acquire 10,750 shares on 09/17/2025.

What was the exercise price paid for the shares in the NRIX Form 4?

The exercise (conversion) price reported for the director stock option was $1.86 per share.

How many NRIX shares does Julia P. Gregory own after the transaction?

The filing shows Ms. Gregory beneficially owned 10,750 shares following the reported transaction.

When does the option exercised by the NRIX director expire?

The derivative security lists an expiration date of 12/22/2029.

What is the vesting history for the option exercised in the NRIX Form 4?

The filing states the option vested 1/48 monthly beginning 9/12/2019 and was fully vested on 8/12/2023.